GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

GSA Capital Partners LLP acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 126,681 shares of the biopharmaceutical company's stock, valued at approximately $1,102,000. GSA Capital Partners LLP owned 0.08% of Ocular Therapeutix as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC raised its position in shares of Ocular Therapeutix by 12.7% in the second quarter. Avoro Capital Advisors LLC now owns 8,060,000 shares of the biopharmaceutical company's stock valued at $55,130,000 after buying an additional 911,064 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company's stock valued at $65,840,000 after buying an additional 2,117,029 shares during the last quarter. Opaleye Management Inc. raised its position in shares of Ocular Therapeutix by 9.6% in the first quarter. Opaleye Management Inc. now owns 6,653,138 shares of the biopharmaceutical company's stock valued at $60,544,000 after buying an additional 583,138 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Ocular Therapeutix in the third quarter valued at about $24,584,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at about $18,514,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Trading Down 7.7 %

OCUL stock traded down $0.76 during mid-day trading on Friday, hitting $9.16. 1,330,624 shares of the company were exchanged, compared to its average volume of 1,860,587. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.43 billion, a P/E ratio of -6.79 and a beta of 1.26. The business has a fifty day simple moving average of $9.88 and a 200-day simple moving average of $8.00. Ocular Therapeutix, Inc. has a 12-month low of $2.05 and a 12-month high of $11.77.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on OCUL. HC Wainwright increased their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday. Robert W. Baird dropped their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. Finally, Scotiabank began coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.